Sarah Lane

University of Tennessee Health Science Center

Papers

1

Total Citations

2

H-Index

1

About

Dr. Sarah Lane is a distinguished clinical researcher whose work focuses on the intersection of radiation oncology and patient-reported outcomes in prostate cancer treatment. Her major contributions center on understanding the nuanced recovery of hormonal function following modern radiotherapy techniques, particularly the combination of short-course androgen deprivation therapy (ADT) with stereotactic body radiotherapy (SBRT). In her highly cited 2019 study, Dr. Lane established a critical correlation between testosterone recovery trajectories and improvements in patient-reported hormonal and sexual domain scores, providing clinicians with evidence-based benchmarks for managing patient expectations during post-treatment recovery. This work has been instrumental in shifting the field toward more patient-centered endpoints, demonstrating that biochemical recovery alone is insufficient without corresponding quality-of-life improvements. Dr. Lane's research has been cited in subsequent clinical guidelines and has influenced the design of de-escalation trials aiming to minimize ADT duration without compromising oncologic outcomes. Her findings continue to shape conversations around survivorship care, offering a framework for integrating patient voice into treatment decision-making.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
Testosterone Recovery Following Short Course Androgen Deprivation Therapy and Stereotactic Body Radiotherapy Correlates Closely with Improvements in Patient-Reported Hormonal and Sexual Domain Scores
2 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: University of Tennessee Health Science Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago